Truce: Moderna backs down in patent fight with NIH as it touts early booster data against Omicron
Moderna has backed down on its patent fight with the NIH, calling a truce by dropping its patent application for now.
Following a heated feud regarding who invented its lifesaving Covid-19 vaccine that was increasingly spilling into public view, the biotech said it “has decided at this time not to pursue” a patent issuance for the mRNA sequence of its jab. But Moderna also filed a continuation application so that some of the claims may still be issued later.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.